menu
    • menu

    Company profile for ImprimisRx

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ImprimisRx® is pioneering a new commercial pathway in the pharmaceutical industry, using compounding pharmacies for the formulation and distribution of high quality, proprietary, compounded formulations. We are patient focused and we do this by partnering with healthcare providers and pharmacy benefit managers to ensure high quality medications at affordable prices for your patients. ImprimisRx® pharmacies are committed to d...
    ImprimisRx® is pioneering a new commercial pathway in the pharmaceutical industry, using compounding pharmacies for the formulation and distribution of high quality, proprietary, compounded formulations. We are patient focused and we do this by partnering with healthcare providers and pharmacy benefit managers to ensure high quality medications at affordable prices for your patients. ImprimisRx® pharmacies are committed to delivering high-quality formulations from our patient specific 503A pharmacy and our FDA-Registered Outsourcing Facility. The healthcare industry is experiencing price increases and shortages for imperative treatments.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImprimisRxUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1705 Route 46 W, Suite 4 Ledgewood, NJ 07852
    Telephone
    Telephone
    858.264.2082
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.imprimisrx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Imprimisrx Announces Leadership Changes
    Imprimisrx Announces Leadership Changes

    06 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/06/3161579/0/en/ImprimisRx-Announces-Leadership-Changes.html

    GLOBENEWSWIRE
    06 Oct 2025
    Share Share
    Enforcement Report - Week of July 30, 2025
    Enforcement Report - Week of July 30, 2025

    30 Jul 2025

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-30-2025-84785.pdf

    FDA
    30 Jul 2025
    Share Share
    Harrow’s ImprimisRx Receives $34.9M Jury Verdict in Lawsuit
    Harrow’s ImprimisRx Receives $34.9M Jury Verdict in Lawsuit

    21 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241121119103/en

    BUSINESSWIRE
    21 Nov 2024
    Share Share
    Enforcement Report - Week of June 19, 2024
    Enforcement Report - Week of June 19, 2024

    19 Jun 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-19-2024-84054.pdf

    FDA
    19 Jun 2024
    Share Share
    Enforcement Report - Week of June 5, 2024
    Enforcement Report - Week of June 5, 2024

    05 Jun 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-5-2024-58484.pdf

    FDA
    05 Jun 2024
    Share Share
    $1 Daraprim? ImprimisRx facility in New Jersey hit with FDA warning letter
    $1 Daraprim? ImprimisRx facility in New Jersey hit with FDA warning letter

    13 Jun 2023

    // Tyler Patchen ENDPTS

    https://endpts.com/1-daraprim-fda-sends-another-warning-letter-to-imprimisrx-facility/

    Tyler Patchen ENDPTS
    13 Jun 2023
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search